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Effect of interleukin-lO treatment on crescentic glomerulonephritis in
rats. This study examined the utility of interleukin-lO (IL-b), a cytokine
with potent anti-macrophage and anti-Tb 1 activity, in the treatment of
experimental anti-glomerular basement membrane (GBM) nephritis in
the rat. Accelerated anti-GBM disease was induced in Sprague-Dawley
rats by immunization with rabbit IgG, followed five days later by an iv.
injection of anti-GBM serum. Groups of four rats received daily s.c.
injections of recombinant mouse IL-b (500, 10 or 0.2 .tgIkgIday) or saline
(control) from the time of anti-GBM serum administration until being
killed on day 14. IL-b treatment suppressed the skin DTH response as
measured by skin thickness (44 to 62% , vs. control, P < 0.05).
Compared to saline controls, IL-b treatment had no beneficial effect on
renal function, proteinuria or histological damage (including crescent
formation) at any dose examined. A detailed analysis of high dose IL-lO
(500 g/kgIday) and saline treated animals was undertaken. Saline con-
trols had marked glomerular macrophage accumulation and proliferation,
which was augmented by IL-lO treatment (46 to 99% 1 and 44 to 143%
¶, respectively; P < 0.05). Immunohistochemical staining found no
difference in the state of macrophage activation between the groups, as
determined by the percentage of macrophages expressing IL-1j3 protein.
Northern blot analysis of whole kidney RNA demonstrated an 830%
increase in IL-1f3 mRNA expression in saline controls compared to
normal rat kidney. High dose IL-b treatment reduced IL-1f3 mRNA
levels by 60% compared to controls (P < 0.05), but did not significantly
reduce glomerular IL-1f3 protein expression. IL-b treatment increased
serum levels of rat anti-rabbit IgG, induced a rat anti-mouse JL-10
response and augmented glomerular deposition of rat C3. In conclusion,
IL-lU was not an effective treatment for rat crescentic anti-GBM glomer-
ulonephritis. This may have been due to the failure of IL-lO to achieve a
sufficient reduction in IL-113 expression and macrophage participation in
disease, or promotion of the Th2 immune response.
Experimental crescentic anti-GBM glomerulonephritis pro-
duces severe renal injury as a result of T cell orchestrated
macrophage accumulation, activation and proliferation, in a char-
acteristic delayed-type hypersensitivity (DTH) response [1, 2].
Interleukin-1f3 (IL-lp) is produced and is of central importance in
both the initiation and progression of rat accelerated anti-GBM
djsease, as shown by the capacity of the IL-i receptor antagonist
(IL-ira) to inhibit renal damage [3].
Interleukin-lO (IL-lU) is a cytokine that is produced by many
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cell types, and in particular, by macrophages and T cells [4, 5]. In
vitro, IL-b is a potent inhibitor of macrophage activation, with
the capacity to inhibit the generation of several molecules that
have been implicated in mediating damage in glomerulonephritis,
such as IL-1J3, tumor necrosis factor-a (TNF-a), macrophage
colony-stimulating factor, reactive oxygen species and matrix
metalloproteinases [2, 4—8]. Additionally, IL-lU inhibits T cell
activation and cytokine release by both inhibiting macrophage
antigen presentation to T cells and through direct effects [9]. This
inhibition is selective, primarily targeting the Thi cytokines
interleukin-2, TNF-a and interferon-y [5, 9, 10]. Thus, in vitro
data suggest that IL-lU should be effective for the suppression of
DTH mediated diseases, such as crescentic glomerulonephritis.
In vivo, IL-b has been well tolerated by both animal and
human recipients [11], and has been shown to inhibit a number of
Thi mediated models of immunologic injury, including: the skin
DTH response, Leishmania infection, experimental autoimmune
encephalomyelitis and collagen induced arthritis [12—15]. Hence,
IL-lU has been demonstrated to be a novel immunosuppressive
agent for diseases involving macrophage and T cell mediated
damage, occurring in the context of a dominant Thi immune
response. While a clear ThlITh2 dichotomy is demonstrable in
specific mouse strains, humans do not exhibit a genetically
determined phenotype, but rather express a mixed response that
is determined by multiple factors [16—18]. In humans, IL-b may
inhibit the cellular immune response but also has the potential to
significantly augment the humoral immune response [19]. There-
fore, the aim of this study was to investigate the effect of IL-lU
treatment in crescentic anti-GBM glomerulonephritis in inbred
Sprague-Dawley rats, a disease model which, like the human
condition, does not have a predetermined Thi or Th2 responder
phenotype. This paper describes the effects of IL-b treatment on
renal structure and function and examines the modulation of the
cellular and humoral mechanisms involved.
Methods
Disease model
Passive accelerated anti-glomerular basement membrane
(GBM) disease was induced in 17 inbred male Sprague-Dawley
rats (150 to 200 g) as described previously [20]. Briefly, rats were
immunized s.c. with 5 mg rabbit IgG in Freund's complete
adjuvant, followed five days later (termed day 0) by an i.v.
injection of 10 mI/kg body wt rabbit anti-rat GBM serum. Groups
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of four rats received a daily s.c. injection of recombinant mouse
IL-b (generously provided by Scherring-Plough, Sydney, Austra-
lia) at three doses (500, 10 or 0.2 jsg/kg) or saline alone (control,
N = 5). Administration of IL-b or saline commenced six hours
prior to the injection of nephrotoxic serum and continued daily
until animals were killed on day 14. IL-lU was diluted in sterile
normal saline, aliquoted, stored at —70°C and thawed immedi-
ately prior to use. In addition, a group of four normal rats was
examined.
Skin delayed-type hypersensitivity response
Twenty-four hours prior to being killed, each animal was given
three separate intradermal injections of 0.1 ml each of rabbit IgG
(1 mglml), sheep IgG (1 mg/ml) and normal saline. Skin thickness
at the time of killing was measured using engineer's callipers.
Hematological parameters, renal function and proteinuria
Blood samples and 24-hour urine collections were taken on
days 1, 4, 7 and 14. White blood cell counts were determined by a
Coulter counter (Cell Dyne) or hemocytometer counts. Measure-
ments of urinary protein excretion (in-house benzathonium chlo-
ride method) and serum and urine creatinine levels (modified
Jaffe method) were performed using a Dupont ARL analyzer by
the Department of Biochemistry, Monash Medical Centre. Twen-
ty-four hour creatinine clearance was determined using the for-
mula UV/P, and the results were corrected for weight to give a
clearance in mi/mm/lOU g rat body wt.
Histopathology
Tissues were fixed in 4% buffered formalin and 4 tm paraffin
sections were stained with the periodic acid-Schiff (PAS) reagent.
Glomerular hypercellularity was assessed by counting the number
of nucleated cells in 25 hilar glomerular cross sections (gcs) per
animal. The percentage of glomeruli exhibiting crescents and
segmental lesions (necrosis, proliferation or hyalinosis) was also
assessed. All scoring was performed on coded slides.
Antibodies
The following mouse monoclonal antibodies (mAb) were used
in this study: EDI, anti-rat CD68 labels most monocytes and
macrophages [21]; MCA 1397, anti-rat recombinant IL-lp (Sero-
tec, Oxford, UK) [22]; 1A29, anti-rat intercellular adhesion
molecule-i (ICAM-i; CD54) [231; anti-human fibronectin, which
detects rat fibronectin [24]; PC-b, anti-rat proliferating cell
nuclear antigen [25]. Peroxidase and alkaline phosphatase-conju-
gated goat anti-mouse IgG, mouse peroxidase anti-peroxidase
complexes (PAP), and mouse alkaline phosphatase anti-alkaline
phosphatase complexes (APAAP) were all purchased from Da-
kopatts (Glostrup, Denmark).
Immunohistochemistiy
Two color immunohistochemical staining was performed as
described previously [261. Tissue from all experimental groups
and normal rats were stained with the ED1 and PC-b mAbs,
while tissues from normal rats and saline treated and IL-b (500
sg!kg/day) treated animals with anti-GBM disease were also
stained for IL-1/3, ICAM and fibronectin expression. In brief, 6
.tm clyostat sections of 2% paraformaldehyde-lysine-periodate
(PLP) fixed tissues (anti-ICAM-1, anti-IL-lp/ED1), snap-frozen
acetone fixed tissues (anti-IL-1/3) and 4 jim paraffin sections
(ED1/PC-iO, anti-fibronectin) of formalin fixed tissues were
blocked with serum then labeled with the primary mAb (as
indicated) overnight at 4°C in 1% BSA in PBS, washed in PBS,
endogenous peroxidase inactivated in 0.3% H202 in methanol,
incubated with peroxidase conjugated goat anti-mouse IgG fol-
lowed by mouse PAP and developed with 3,3-diaminobenzidine to
produce a brown color. Next, sections were heated for 10 minutes
in a microwave oven to block antibody cross-reactivity and
inactivate endogenous alkaline phosphatase [26], blocked with
serum as above, then incubated sequentially with a ED1 or PC-lU,
alkaline phosphatase-conjugated goat anti-mouse IgG and mouse
APAAP, then developed with Fast Blue BB Salt (Ajax Chemicals,
Melbourne, Australia). Sections were counterstained with PAS
without hematoxylin and mounted with aqueous medium.
Slides were coded and then scored. Single and double positive
cells were counted in at least 20 gcs for ED1, PC-b, EDI/PC-lO
and ED1/IL-lp stained sections. In addition, a semiquantitative
scoring method was used for sections stained with anti-IL-1f3,
anti-fibronectin and anti-ICAM-1 mAb, as follows: 0 = no
staining; 1 = <25% stained; 2 = 25 to 50% stained; 3 = >50% of
the ges stained.
Probes
A 1.26 kb eDNA fragment of rat IL-113 (Accession # M98820)
and a 0.98 kb eDNA fragment of rat transforming growth
factor-1 (TGF-/3) [27], were prepared by reverse transcription
PCR and cloned into the pMOSBlue T-vector (Amersham Inter-
national, Buckinghamshire, UK). The eDNA for rat monocyte
chemoattractant protein-i (MCP-1) was provided by Dr. Teizo
Yoshimura [28]. Anti-sense digoxigenin (DIG) labeled cRNA
probes were prepared using a RNA labeling kit, according to the
manufacturer's instructions (Boehringer Mannheim GmbH,
Mannheim, Germany). A 358 bp fragment of rat glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) eDNA [291 was amplified
by reverse transcription PCR and DIG-labeled using the High-
Prime random priming kit (Boehringer Mannheim GmbH).
Northern blot analysis
Northern blot analysis using DIG-labeled probes and chemilu-
minescence detection was performed as previously described [30].
Total cellular RNA was extracted from one half of one kidney
obtained from normal and diseased rats (saline treated and IL-b
treated 500 jig/kg/day only) using RNAzoI-B according to the
manufacturer's protocol (Biotec Lab. Inc. Houston, TX, USA).
RNA (20 jig/sample) was denatured with glyoxal and dimethyl-
suiphoxide, fractionated on a 1.2% agarose gel and capillary
blotted onto Hybond-N-membrane (Amersham). Membranes
were hybridized with DIG-labeled probes for rat MCP-1, IL-i13,
TGF-/3 and GAPDH. Bound probes were detected by chemilu-
minescence captured into Kodak XAR film (Eastman Kodak,
Rochester, NY, USA). Densitometric analysis of films used the
Cue 2 Image Analyser programme (Olympus). All results are
expressed relative to the GAPDH signal.
Measurement of the humoral response
Circulating levels of rat IgG reactive with rabbit immunoglob-
ulin and rat IgG reactive with recombinant mouse IL-b were
quantitated by a sandwich ELISA, as previously described [31].
Deposition of humoral reactants within the kidney was assessed
by direct immunofluorescence staining of cryostat tissue sections
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Fig. 1. Skin DTH response. Saline treated controls had a significant
increase in skin thickness at the site of intra-dermal injection of rabbit IgG
after 24 hours. Treatment with IL-b, at all doses tested, significantly
inhibited the increase in skin thickness in response to rabbit IgG. ##P <
0.01, ###P < 0.001 versus normal; *P < 0.05 versus saline controls.
with FITC-conjugated antibodies against rat IgG and C3. Sections
from each animal were labeled with serial twofold dilutions of
each antibody and scored for the titer at which immunofluores-
cence staining was lost.
Statistical analysis
Data are presented as mean I SD. Comparisons were made
between the four groups of animals by the analysis of variance
(ANOVA, using the Bonferroni correction for multiple compar-
isons). Further experiments comparing saline treated rats with
those given IL-b 500 j.tglkglday were made by applying either an
unpaired, two-sided Student's t-test or a Mann-Whitney U-test
(for non-parametric data).
Results
Skin DTH response
Skin thickness was equivalent in all groups at sites of saline and
sheep IgG intradermal injection. Intradermal injection of rabbit
IgG produced an increase in skin thickness in all saline and IL-b
treated animals (Fig. 1). Skin swelling (skin thickness at site of
rabbit IgG injection — thickness at saline injection site) was
reduced by 44 to 62% in IL-b treated animals, as compared to
saline treated controls (P < 0.05 for all doses of IL-b).
Hematological effects
All doses of IL-b induced an exaggerated leukocytosis on day
1 of anti-GBM disease compared to saline treated animals,
although this failed to reach statistical significance (15 to 71% t
P = NS). This was an acute effect, with white cell counts
comparable to those of saline treated controls on days 7 and 14.
Glomerular injuly and renal function
Proteinuria developed in all animals and increased throughout
the experiment (Fig. 2a). No significant differences were seen
between the different treatment groups at any time point.
0 1 4 7 14
Time, days after injection of anti-GBM serum
Fig. 2. Effect of IL-JO treatment on proteinuria and creatinine clearance in
rat anti -GBM disease. (A) Twenty-four hour proteinuria increased
throughout the 14 day time course. No significant differences were seen
between the treatment and control groups. (B) Creatinine clearance fell at
day I and remained depressed through to day 14 in all groups (P < 0.05
vs. controls at day 0). Symbols are: (LII) saline; (L:;) 0.2 pg/kg; (LI) 10 p.g/kg;(•) 500 /Lg/kg.
Creatinine clearance fell below normal in all groups at day 1(37
to 44% . , P < 0.01), and remained reduced in all groups at all
time points (Fig. 2b). Creatinine clearances were not different
between the different treatment and control groups.
Histological inJuiy
Moderate glomerular hypercellularity was seen in all animals
on day 14 of anti-GBM disease, with no significant differences
between the IL-b and saline treated groups (Fig. 3a). Similarly,
there was no difference in the percentage of glomeruli exhibiting
focal lesions between the groups (Fig. 3b). Crescent formation
was detected in 34% of glomeruli in saline controls (Fig. 3c).
IL-b treated animals had crescents in 40 to 54% of glomeruli,
though this increase in the number of glomeruli exhibiting cres-
cents was not significantly different in any of the treatment groups
as compared to saline treated controls. Glomerular matrix depo-
sition was assessed by immunohistochemistry staining for fi-
bronectin. All saline treated animals had 3 + glomerular staining
for fibronectin, compared to 1+ for normal glomeruli. High dose
IL-b treatment also showed a glomerular 3+ score in all animals.
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Fig. 3. Histological renal damage on day 14 in rat anti-GBM disease. (A)
Moderate glomerular hypercellularity was seen in all groups (P < 0.05 vs.
normals 64 4.6 cellslgcs). (B) Focal lesions were seen in most glomcruli
in all groups. (C) Crescents were present in 34% of glomeruli in control
animals and in 40 to 54% of animals treated with IL-b (non-significant
increase in all tL-I0 treated groups vs. saline controls).
Macrophage involvement in disease
Chemotaxis. Monocyte chemoattractant protein-I (MCP-I) is a
chemokine known to participate in renal macrophage infiltration
in glomerulonephritis [321. Whole kidney MCP-1 mRNA expres-
sion was up-regulated 10-fold in saline treated animals on day 14
of anti-GBM disease compared to normal rats (Fig. 4). High dose
IL-b treatment reduced MCP-1 mRNA by 80% compared to
saline treated animals (P < 0.05), although this was still elevated
compared to normal rats.
Adhesion. Up-regulation of renal ICAM-1 (CD54) expression is
known to participate in renal macrophage infiltration in glomer-
ulonephritis [33, 34]. Immunohistochemistry staining showed a
marked upregulation of glomerular expression of ICAM-1 (all
animals 3+ vs. 1+ in normal animals). This was not altered by
high dose IL-b treatment.
Glomerular macrophage accumulation. There was a marked
glomerular macrophage accumulation in saline treated animals on
day 14 of anti-GBM disease compared to normal rats (6.8 1.0
vs. 1.0 0.2 EDI+ cells/gcs; P < 0.001; Figs. 5 and 6a). IL-b
treatment caused a dose-dependent increase in glomerular mac-
rophage accumulation compared to saline treated animals (Figs. 5
and 6a). Local macrophage proliferation was assessed by double
immunohistochemistry staining with EDI and PC-b antibodies.
Glomerular macrophage proliferation (ED1PCNA cells) was
detected in saline treated controls, but was negligible in normal
rats (Figs. 5 and 6b). High dose IL-b treatment caused an
increase in the number of proliferating glomerular macrophages
compared to saline treated animals (Figs. 5 and 6b). There was
also a trend towards IL-b treatment causing an increase in the
total number of glomerular proliferating cells, but this did not
reach statistical significance (Fig. 6c).
Macrophage activation. Interleukin-1f3 expression was used as
an index of macrophage activation. No ED1IL-1p macro-
phages were detected in glomeruli from normal rats, however,
ED1IL-1f3 macrophages were detected in both saline and
IL-b treated animals (Fig. 5 d-f). When expressed as a percent-
age of the total macrophage infiltrate, there was no difference in
macrophage IL-1/3 expression between the high dose IL-b and
saline treated groups (8.4 1.6 vs. 8.3 2.3%, P = NS).
Cytokine production
Interleukin 113. Northern blot analysis showed an 830% upregu-
lation of IL-1f3 mRNA, relative to GAPDH mRNA, in whole
kidney from saline treated anti-GBM disease versus normal
kidneys (Fig. 4). IL-b treatment resulted in a significant, partial
inhibition of IL-113 up-regulation in anti-GBM disease, and the
levels remained elevated in comparison to normal animals (Fig.
4). Semiquantitative scoring of antibody stained sections con-
firmed an increase in glomerular IL-113 expression in saline
treated disease versus normal animals (2.7 0.08 vs. 0.95 0.08,
respectively; P < 0.05). Notably, the most intense IL-113 staining
was tubular. IL-b treatment caused a minor, non-significant
reduction in IL-1p staining compared to saline controls (2.3
0.27 vs. 2.7 0.08, respectively; P = NS).
Transforming growth factor-13 (TGF-j3). Northern blot analysis
of whole kidney RNA showed an up-regulation of TGF-/3 mRNA
in saline treated disease, which was exacerbated by treatment with
IL-b 500 xg/kg/day (IL-b vs. saline controls, 36% increase, P =
NS; IL-b vs. normals, 107% increase, P < 0.05; Fig. 4).
Humoral response
Serum levels of rat anti-rabbit IgG antibody were increased
twofold in high dose IL-b compared to saline treated animals
(Fig. 7b). This was evident on both days 7 and 14. Treatment with
lower doses of IL-I 0 did not affect serum antibody titers (data not
shown). Au animals receiving recombinant mouse IL-b mounted
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1100 Fig. 4. Northern blot analysis of cytokine gene
expression in rat anti-GBM disease. Total cellular
900 RNA was extracted from whole kidney from
I normal animals and from animals with anti-700 * GBM disease which had been treated with
either saline or IL-b 500 .rg/kg/day. (A) Blots
' 500 were probed for expression of IL-i j3, MCP-1
* # and TGF-f3 mRNA, using GAPDH as a
300 control. (U) Densitometric analysis, expressed
as the ratio of cytokine gene: GAP-DH,0 100 normalized to the levels obtained from normal
— — __________ — ___________________ kidney (100% so). Symbols are: () normals;
IL-i ' ''P 1 TGF-° (U) controls; (•) IL-b. #P < 0.05 versusF' "'' - F' normal; * < 0.05 versus controls.
a humoral immune response to the cytokine as shown by the receiving high dose IL-b compared to saline treated rats (1/2800
presence of serum anti-IL-lO IgG antibodies, which were absent dilution vs. 1/4000 dilution, respectively; P NS).
in saline treated animals (Fig. 6b).
Deposition of rat IgG and C3 in glomeruli was assessed by Discussion
semiquantitative immunofluorescence staining. There was no In this model of crescentic glomerulonephritis, treatment with
difference in rat IgG deposition between any of the experimental IL-b was not beneficial. The administration of IL-b in this study
groups (all scored at a 1/4000 dilution). However, there was a reduced skin DTH to a similar degree to that which has beert
trend towards an increase in glomerular C3 deposition in rats reported [12]. Thus, the effective delivery of bioactive IL-b was
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Fig. 5. Immunohistochemical demonstration of glomerular macrophage accumulation and prolifrration (a-c), and glomerular IL-I /3 expression (d-J), at day
14 in rat anti -GBM disease. (a) Double staining with ED1 (brown) and PC-b (blue) in normal rat kidney showing one PCNA+ glomerular cell and a
few interstitial EDI+ macrophages. (b) Saline treated anti-GBM disease showing a marked increase in glomerular PCNA+ cells. A significant EDI+
macrophage infiltrate is also present, some of which are proliferating (arrow). (c) High dose IL-ID treatment of anti-GBM disease caused a marked
exacerbation of glomerular ED1+ macrophage accumulation, many of which were proliferating. (d) Weak constitutive IL-1/3 expression (brown) is
evident in normal rat kidney. (e) Saline treated anti-GBM disease shows an increase in glomerular IL-1/3 expression, including expression by several
infiltrating ED1 + (blue) macrophages (double stained, arrow). (fl A similar proportion of EDI + macrophages showed IL-l/3 expression in high dose
IL-b treated animals (arrows). Panels b, c, e, and f were counterstained with PAS minus hematoxylin. Original magnification X400.
demonstrated. Why then did IL-b fail to suppress nephritis? Two
probable explanations exist: (1) IL-lO treatment failed to ade-
quately suppress the mechanisms of T cell/macrophage mediated
renal injury that were, on the basis of in vitro data, predicted to be
susceptible; and/or (2) IL-it) facilitated renal damage via humoral
mechanisms.
IL-1 was strongly expressed in rat kidney during anti-GBM
disease, dominantly by tubules and also within the glomerulus.
IL-b treatment caused partial suppression of IL-1/3 mRNA
expression in whole kidney, the majority of which may be of
tubular origin, but had no significant effect upon glomerular IL-1/3
protein staining. This issue may be the key to the failure of IL-lb
treatment of this disease. IL-1/3 is a strong inducer of chemokines,
such as MCP-1, and leukocyte adhesion molecules, such as
ICAM-1, both of which are known to participate in renal macro-
phage infiltration [32—34]. The partial inhibition of IL-1/3 expres-
sion that was seen with IL-JO treatment caused only a partial
reduction in renal MCP-1 expression and failed to affect the
up-regulation of glomerular ICAM-1 expression. Furthermore,
IL-ira treatment of this model has been shown to cause a
reduction in local macrophage proliferation [31]. IL-b treatment
failed to suppress macrophage proliferation within the glomeru-
lus, again pointing to an inability to adequately inhibit renal IL-1p
expression. In contrast to the proven in vitro capacity of IL-b to
inhibit macrophage activation [5, 6], we found no difference in the
activation state of glomerular macrophages between saline and
IL-b treated animals in this model. Therefore, IL-b failed to
inhibit macrophage accumulation and activation within the gb-
merulus. The differences found between the in vitro and in vivo
effects of IL-b may relate to the complexity of the inflammatory
response in vivo [12].
In vitro, IL-b inhibits the release of cytokines that promote a
Thi response, thereby promoting the survival of Th2 cells and the
formation of a predominantly Th2 immune response [5, 10]. As
IL-b also enhances the viability of B cells and enhances macro-
phage Fey receptor expression [35, 36], the combined effects of
these actions may result in the promotion of the humoral response
in vivo. This effect has been demonstrated in murine lupus
nephritis, in which IL-b treatment accelerated renal death, and
conversely anti-IL-lO antibody administration delayed the onset
of autoantibody production and prolonged survival [37]. In addi-
tion, 10 xg/kg IL-b pretreatment of OKT3 therapy for renal
albograft rejection in humans was found to promote anti-OKT3
antibody formation, causing a loss of efficacy of OKT3 treatment
[19]. In the present experiment, we found evidence of an exag-
gerated humoral immune response as shown by an increase in
serum levels of rat anti-rabbit IgG. Additionally, animals treated
with IL-JO developed an antibody response to the administered
cytokine and showed an augmented C3 deposition within the
glomerulus. Indeed, deposition of antibody-IL-b immune com-
plexes within the gbomerulus may well explain the marked in-
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Fig. 6. Quantitalion of glomerular macrophage accumulation and prolifer-
ation at day 14 in rat anti-GBM disease. (A) Double immunohistochemistry
staining showed a significant glomerular macrophage (ED1 + cells) accu-
mulation in saline treated disease controls, which was further increased in
a dose dependent fashion by treatment with IL-b. (B) Macrophage
proliferation (EDI +PCNA+ cells) was dramatically increased in controls,
and was further increased by IL-iD treatment in a dose dependent fashion.
(C) Total proliferating cells (PCNA+ cells) were increased in saline
treated controls, but this was not affected by IL-ID treatment disease.
Symbols are: () normal; (El) saline; (El) 0.2 g IL-b; () 10 jxg IL-tO;(•) 500 jg IL-lO; #P < 0.05, ##P < 0.01 and ###P < 0.001 versus
normals; *O < 0.05 and **p < 0.01 versus saline controls.
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Fig. 7. Antibody response at day 14 of rat anti-GBM disease. (A) Titration
of the rat anti-rabbit IgG response in saline treated (circle) and 500 jrg/kg
IL-b treated (triangle) animals. (B) 500 pg/kg IL-lO treated (triangle)
rats developed an anti-recombinant murine IL-b IgG response, that was
not seen in saline treated (circle) animals.
crease in glomerular macrophage infiltration and proliferation
seen in the high dose IL-b treated group. Ideally, treatment in
this rat model with recombinant rat IL-b may have reduced the
development of rat anti-rIL-lO antibodies and thereby decreased
the risk of immune complex deposition.
In conclusion, this study demonstrated that IL-b treatment had
no beneficial effect upon a rat model of rapidly progressive
crescentic glomerulonephritis. IL-b was able to partially suppress
renal up-regulation of IL-1/3, but this was not sufficient to prevent
known IL-lp dependent mechanisms of renal injury. Additionally,
IL-b appeared to facilitate renal damage via the humorallTh2
immune response. This indicates that while IL-b may be an
effective inhibitor of Thi dependent inflammatory conditions in
specific mouse models, it may be less effective when there is not a
mutually exclusive Thi or Th2 immune response, such as in
human glomerulonephritis.
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